EX-99.2 3 rkda-ex99_2.htm EX-99.2 EX-99.2

 

Exhibit 99.2

img193038000_0.jpg

 

Arcadia Biosciences, Inc.

Consolidated Balance Sheets

(Unaudited)

(In thousands, except share data)

 

 

 

 

 

 

 

 

 

 

September 30, 2026

 

 

December 31, 2025

 

Assets

 

 

 

 

 

 

Current assets:

 

 

 

 

 

 

Cash and cash equivalents

 

$

2,844

 

 

$

259

 

Short-term investments

 

 

—

 

 

 

4,304

 

Accounts receivable and other receivables, net of allowance for credit loss
   of $559 as of September 30, 2026 and December 31, 2025

 

 

625

 

 

 

425

 

Inventories

 

 

973

 

 

 

1,212

 

Prepaid expenses and other current assets

 

 

120

 

 

 

156

 

Total current assets

 

 

4,562

 

 

 

6,356

 

Property and equipment, net

 

 

—

 

 

 

8

 

Intangible assets, net

 

 

39

 

 

 

39

 

Other noncurrent assets

 

 

115

 

 

 

143

 

Total assets

 

$

4,716

 

 

$

6,546

 

Liabilities and stockholders’ equity

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

Accounts payable and accrued expenses

 

$

1,010

 

 

$

1,789

 

Other current liabilities

 

 

263

 

 

 

270

 

Total current liabilities

 

 

1,273

 

 

 

2,059

 

Common stock warrant and option liabilities

 

 

1,040

 

 

 

347

 

Total liabilities

 

 

2,313

 

 

 

2,406

 

Commitments and contingencies (Note 13)

 

 

 

 

 

 

Stockholders’ equity:

 

 

 

 

 

 

Common stock, $0.001 par value—150,000,000 shares authorized as
   of September 30, 2026 and December 31, 2025; 5,131,211 and 1,373,120 shares issued
   and outstanding as of September 30, 2026 and December 31, 2025, respectively

 

 

67

 

 

 

65

 

Additional paid-in capital

 

 

292,449

 

 

 

285,292

 

Accumulated deficit

 

 

(290,113

)

 

 

(281,217

)

Total stockholders' equity

 

 

2,403

 

 

 

4,140

 

Total liabilities and stockholders’ equity

 

$

4,716

 

 

$

6,546

 

 

 

1


 

Arcadia Biosciences, Inc.

Consolidated Statements of Operations and Comprehensive Income (Loss)

(Unaudited)

(In thousands, except share data and per share data)

 

 

 

Three Months Ended September 30,

 

 

Nine Months Ended September 30,

 

 

 

 

2026

 

 

 

2025

 

 

 

2026

 

 

 

2025

 

Revenues:

 

 

 

 

 

 

 

 

 

 

 

 

Product

 

$

1,619

 

 

$

1,302

 

 

$

4,162

 

 

$

3,957

 

Total revenues

 

 

1,619

 

 

 

1,302

 

 

 

4,162

 

 

 

3,957

 

Operating expenses (income):

 

 

 

 

 

 

 

 

 

 

 

 

Cost of revenues

 

 

760

 

 

 

884

 

 

 

2,272

 

 

 

2,389

 

Research and development

 

 

—

 

 

 

—

 

 

 

—

 

 

 

9

 

Gain on sale of intangible assets

 

 

—

 

 

 

—

 

 

 

—

 

 

 

(750

)

Change in fair value of contingent consideration

 

 

—

 

 

 

—

 

 

 

—

 

 

 

(2,000

)

Selling, general and administrative

 

 

1,698

 

 

 

1,570

 

 

 

4,004

 

 

 

5,434

 

Total operating expenses

 

 

2,458

 

 

 

2,454

 

 

 

6,276

 

 

 

5,082

 

Loss from continuing operations

 

 

(839

)

 

 

(1,152

)

 

 

(2,114

)

 

 

(1,125

)

Interest income

 

 

20

 

 

 

7

 

 

 

27

 

 

 

222

 

Credit loss

 

 

—

 

 

 

(257

)

 

 

—

 

 

 

(4,745

)

Other income (loss), net

 

 

—

 

 

 

1,698

 

 

 

(4,285

)

 

 

2,770

 

Loss on January 2026 Inducement Offer

 

 

—

 

 

 

—

 

 

 

(2,877

)

 

 

—

 

Valuation loss on June 2026 PIPE

 

 

—

 

 

 

—

 

 

 

(5,423

)

 

 

—

 

Change in fair value of common stock warrant and option liabilities

 

 

2,574

 

 

 

560

 

 

 

6,848

 

 

 

1,875

 

Issuance and offering costs

 

 

—

 

 

 

—

 

 

 

(1,072

)

 

 

—

 

Net income (loss) attributable to common stockholders

 

$

1,755

 

 

$

856

 

 

$

(8,896

)

 

$

(1,003

)

Net income (loss) per share attributable to common stockholders:

 

 

 

 

 

 

 

 

 

 

 

 

Basic

 

$

0.29

 

 

$

0.63

 

 

$

(2.39

)

 

$

(0.73

)

Diluted

 

$

0.29

 

 

$

0.62

 

 

$

(2.39

)

 

$

(0.73

)

Weighted-average number of shares used in per share
   calculations:

 

 

 

 

 

 

 

 

 

 

 

 

Basic

 

 

6,065,211

 

 

 

1,367,192

 

 

 

3,728,138

 

 

 

1,366,768

 

Diluted

 

 

6,065,211

 

 

 

1,371,879

 

 

 

3,728,138

 

 

 

1,366,768

 

 

2


 

Arcadia Biosciences, Inc.

Consolidated Statements of Cash Flows

(Unaudited)

(In thousands)

 

 

Nine Months Ended September 30,

 

 

 

 

2026

 

 

 

2025

 

CASH FLOWS FROM OPERATING ACTIVITIES:

 

 

 

 

 

 

Net loss

 

$

(8,896

)

 

$

(1,003

)

Adjustments to reconcile net loss to cash used in operating activities:

 

 

 

 

 

 

Change in fair value of common stock warrant and option liabilities

 

 

(6,848

)

 

 

(1,875

)

Change in fair value of contingent consideration

 

 

—

 

 

 

(2,000

)

Issuance and offering costs

 

 

1,072

 

 

 

—

 

Valuation loss on June 2026 PIPE

 

 

5,423

 

 

 

—

 

Loss on January 2026 Inducement Offer

 

 

2,877

 

 

 

—

 

Depreciation

 

 

8

 

 

 

30

 

Lease amortization

 

 

—

 

 

 

122

 

Amortization of note receivable

 

 

—

 

 

 

(69

)

Gain on sale of intangible assets

 

 

—

 

 

 

(750

)

Gain on receipt of Above Food Ingredients, Inc. common stock

 

 

—

 

 

 

(1,067

)

Unrealized loss (gain) subsequent to receipt of Above Food Ingredients, Inc. common stock

 

 

4,304

 

 

 

(1,698

)

Stock-based compensation

 

 

43

 

 

 

217

 

Credit loss

 

 

—

 

 

 

4,745

 

Changes in operating assets and liabilities:

 

 

—

 

 

 

—

 

Accounts receivable and other receivables

 

 

(200

)

 

 

(241

)

Inventories

 

 

239

 

 

 

(552

)

Prepaid expenses and other current assets

 

 

36

 

 

 

717

 

Other noncurrent assets

 

 

—

 

 

 

(56

)

Accounts payable and accrued expenses

 

 

(748

)

 

 

(172

)

Amounts due to related parties

 

 

—

 

 

 

(30

)

Other current liabilities

 

 

(7

)

 

 

(57

)

Operating lease liabilities

 

 

—

 

 

 

(139

)

Net cash used in operating activities

 

 

(2,697

)

 

 

(3,878

)

CASH FLOWS FROM INVESTING ACTIVITIES:

 

 

 

 

 

 

Proceeds from sale of intangible assets

 

 

—

 

 

 

750

 

Net cash provided by investing activities

 

 

—

 

 

 

750

 

CASH FLOWS FROM FINANCING ACTIVITIES:

 

 

 

 

 

 

Proceeds from June 2026 PIPE

 

 

4,000

 

 

 

—

 

Payments of offering costs relating to June 2026 PIPE

 

 

(450

)

 

 

—

 

Proceeds from January 2026 Inducement Offer

 

 

2,082

 

 

 

—

 

Payments of offering costs relating to January 2026 Inducement Offer

 

 

(350

)

 

 

—

 

Proceeds from ESPP purchases

 

 

—

 

 

 

6

 

Net cash provided by financing activities

 

 

5,282

 

 

 

6

 

Net increase (decrease) in cash and cash equivalents

 

 

2,585

 

 

 

(3,122

)

Cash and cash equivalents — beginning of period

 

 

259

 

 

 

4,242

 

Cash and cash equivalents — end of period

 

$

2,844

 

 

$

1,120

 

NONCASH INVESTING AND FINANCING ACTIVITIES:

 

 

 

 

 

 

Preferred investment options issued to placement agent and included in offering costs related to June 2026 PIPE

 

$

201

 

 

$

—

 

Preferred investment options issued to placement agent and included in offering costs related to January 2026 Inducement Offer

 

$

71

 

 

$

—

 

Warrant and option modifications included in Loss on January 2026 Inducement Offer

 

$

555

 

 

$

—

 

Fair value of Above Food Ingredients, Inc. common stock received

 

$

—

 

 

$

3,067

 

 

# # #

3